Cargando…

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma

A non-immunogenic tumor microenvironment (TME) is a significant barrier to immune checkpoint blockade (ICB) response. The impact of Polybromo-1 (PBRM1) on TME and response to ICB in renal cell carcinoma (RCC) remains to be resolved. Here we show that PBRM1/Pbrm1 deficiency reduces the binding of bra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xian-De, Kong, Wen, Peterson, Christine B., McGrail, Daniel J., Hoang, Anh, Zhang, Xuesong, Lam, Truong, Pilie, Patrick G., Zhu, Haifeng, Beckermann, Kathryn E., Haake, Scott M., Isgandrova, Sevinj, Martinez-Moczygemba, Margarita, Sahni, Nidhi, Tannir, Nizar M., Lin, Shiaw-Yih, Rathmell, W. Kimryn, Jonasch, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195420/ https://www.ncbi.nlm.nih.gov/pubmed/32358509 http://dx.doi.org/10.1038/s41467-020-15959-6

Ejemplares similares

Renal cell carcinoma
por: Jonasch, Eric, et al.
Publicado: (2014)

Modeling Clear Cell Renal Cell Carcinoma and Therapeutic Implications
por: Wolf, Melissa M., et al.
Publicado: (2020)

Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers
por: McGrail, Daniel J., et al.
Publicado: (2018)

OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)
por: Beckermann, Kathryn, et al.
Publicado: (2023)

SET-ing the stage for PI3Kβ inhibitor sensitivity in clear cell renal cell carcinoma
por: Pilié, Patrick G., et al.
Publicado: (2019)

Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma
por: Pilié, Patrick G., et al.
Publicado: (2017)

IMMUNE RESPONSE TO A HAPTEN COUPLED TO A NONIMMUNOGENIC CARRIER : INFLUENCE OF LIPOPOLYSACCHARIDE
por: Schmidtke, Jon R., et al.
Publicado: (1972)

Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway
por: Zhang, Jing, et al.
Publicado: (2023)

PBRM1 suppresses tumor growth as a novel p53 acetylation reader
por: Cai, Weijia, et al.
Publicado: (2020)

Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins
por: McGrail, Daniel J., et al.
Publicado: (2023)

Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
por: Beckermann, Kathryn E., et al.
Publicado: (2017)

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma
por: Aili, Abudureyimujiang, et al.
Publicado: (2021)

A Lubricated Nonimmunogenic Neural Probe for Acute Insertion Trauma Minimization and Long‐Term Signal Recording
por: Lee, Yeontaek, et al.
Publicado: (2021)

Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma
por: Murakami, A, et al.
Publicado: (2017)

PBRM1 Regulates Stress Response in Epithelial Cells
por: Porter, Elizabeth G., et al.
Publicado: (2019)

A Gene Expression Signature to Predict Nucleotide Excision Repair Defects and Novel Therapeutic Approaches
por: Wei, Rongbin, et al.
Publicado: (2021)

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma
por: Msaouel, Pavlos, et al.
Publicado: (2017)

The Induction of Enhanced Antitumor Effect against a Nonimmunogenic Tumor by Highly Immunogenic Variants Obtained by Mutagen Treatment
por: Sainouchi, Ryouhei, et al.
Publicado: (1988)

Theoretical premises of a “three in one” therapeutic approach to treat immunogenic and nonimmunogenic cancers: a narrative review
por: Proskurina, Anastasia S., et al.
Publicado: (2021)

Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)
por: Ghatalia, Pooja, et al.
Publicado: (2018)

The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
por: Lim, Aaron R, et al.
Publicado: (2020)

PBRM1 bromodomains associate with RNA to facilitate chromatin association
por: De Silva, Saumya M, et al.
Publicado: (2023)

Untangling ccRCC prognosis with SLINKY
por: Reinfeld, Bradley I., et al.
Publicado: (2017)

COVID-19 impact on early career investigators: a call for action
por: Levine, Ross L., et al.
Publicado: (2020)

Role of the Pbrm1 subunit and the PBAF complex in Schwann cell development
por: Polanetzki, Vanessa, et al.
Publicado: (2022)

A Pan-Cancer Analysis of the Role of PBRM1 in Human Tumors
por: Liu, Jin, et al.
Publicado: (2022)

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers
por: Dai, Jiali, et al.
Publicado: (2023)

Influenza Virus–induced Dendritic Cell Maturation Is Associated with the Induction of Strong T Cell Immunity to a Coadministered, Normally Nonimmunogenic Protein
por: Brimnes, Marie K., et al.
Publicado: (2003)

PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth
por: Cai, Weijia, et al.
Publicado: (2019)

The therapeutic implications of immunosuppressive tumor aerobic glycolysis
por: Reinfeld, Bradley I., et al.
Publicado: (2021)

Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
por: Carril-Ajuria, Lucía, et al.
Publicado: (2019)

Pbrm1 intrinsically controls the development and effector differentiation of iNKT cells
por: Wang, Xin, et al.
Publicado: (2022)

Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma
por: Beckermann, Kathryn, et al.
Publicado: (2023)

Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies
por: Rathmell, Kimryn W., et al.
Publicado: (2015)

Nucleostemin Reveals A Dichotomous Nature of Genome Maintenance in Mammary Tumor Progression
por: Lin, Tao, et al.
Publicado: (2019)

HIF1α and HIF2α Exert Distinct Nutrient Preferences in Renal Cells
por: Arreola, Alexandra, et al.
Publicado: (2014)

IMMUNOLOGICAL TOLERANCE IN BONE MARROW-DERIVED LYMPHOCYTES : III. TOLERANCE INDUCTION IN PRIMED B CELLS BY HAPTEN CONJUGATES OF UNRELATED IMMUNOGENIC OR "NONIMMUNOGENIC" CARRIERS
por: Katz, David H., et al.
Publicado: (1974)

Mrs. Einstein
por: McGrail, Anna
Publicado: (1998)

Surmortalité, COVID-19 et systèmes de santé au Canada
por: McGrail, Kimberlyn
Publicado: (2022)

Excess mortality, COVID-19 and health care systems in Canada
por: McGrail, Kimberlyn
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d8s0lpcmtqo24kpmfuguo817cc